Work

Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs21-ot2-18-01

Authors: Alexandra Torres, Carey Kokkonen, Mary Oladeji, Kurt D'Andrea, Rosemarie Mick, Vivek Narayan, Michael Mallamaci, Gayle Ewing, Hayley Knollman, Nadine M. Tung, Mark Robson, Katherine L. Nathanson, Susan Domchek, Payal D. Shah

Institutions: University of Pennsylvania, AstraZeneca (United States), Beth Israel Deaconess Medical Center, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4220789522

Cites:

Cited by: 3

Related to: 10